Study: Bayer drug boosts TB treatment

A Bayer drug got huzzahs from TB researchers as the first novel antibiotic in 25 years to improve treatment of the increasingly widespread disease. Researchers found that adding Avelox (moxifloxacin) to a standard TB-fighting drug combo cut treatment time significantly, boosting infection clearance at the two-month mark by 17 percent.

TB treatment is a big market, with 9 million people contract TB every year. And it's a market that needs help: As many as 1.5 million TB patients die annually.

- see this Johns Hopkins release

ALSO:  Bill & Melinda Gates Foundation announced today grants totaling $280 million to help fight tuberculosis. The 11 new grants will speed research and development on promising vaccines, diagnostic tests, and treatments to help reduce the global TB burden. Release

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.